Ardian Buyout’s Post

While many mergers and acquisitions were suspended with the arrival of COVID, the industry bore witness to some of the largest deals on record. In 2019, we saw almost 700 strategic deals – the most since 2010. PharmaCircle looks at the top 5 largest Big Pharma deals leading up to COVID and how they are impacting current pipelines. Learn more in The Weekly Brief https://lnkd.in/eCbZrP9. #M&As #Partnerships #BigPharma #PharmaCircle

Companies to Watch for Potential M&As in 2024 https://lnkd.in/gwNeNXVk Hand passing off bag of money over financial background/Taylor Tieden for BioSpace This year has seen a boom in biopharma mergers and acquisitions, with six acquisitions over a billion dollars so far. In light of [...]

Shaping the Future: A Week of Strategic Mergers and Acquisitions Redefining Industries March's M&A Blitz: #FranciscoPartners leads with #JamaSoftware at $1.2B, followed by #GileadSciences' $4.3B acquisition of CymaBay Therapeutics. Amex GBT enters the fray with a $570 million takeover of #CWT. #GTCR secures Cloudbreak Health for $180 million, Further expands with Pandata, and ACU-Serve bolsters its healthcare footprint with Beyond HME. Gordon Brothers rounds it off, acquiring Catch Co.'s assets. These strategic moves redefine industries, fostering innovation and competitive advantage in an ever-evolving landscape. Partner with Allied Market Research to navigate this dynamic landscape and script your success narrative: https://lnkd.in/dd-xe5Fr #MergersAndAcquisitions #IndustryTransformations #AMR #StrategicMoves #MarketInsights #InnovationInBusiness #GrowthOpportunities #IndustryLeadership #Cloudbreak #BusinessGrowth

Exciting developments in the biopharma industry! In 2023, mergers and acquisitions took center stage, surpassing the dealmaking highs of recent years. The top 10 M&A deals in biopharma reached an impressive $115.8 billion, outpacing the totals of 2022, 2021, and 2020 at $65 billion, $53 billion, and $97 billion. It's clear that the industry is on a robust growth trajectory, paving the way for innovation and collaboration. Here's to a dynamic future in biopharma! Read the full report! https://ow.ly/APjZ50QxXNg Want to learn more about biopharma M&A, including how to build a comprehensive business development strategy? Join leading dealmaking experts from top biopharma companies at the Fierce BD&L Summit in San Francisco on March 11-12th. Save $300 when you register before Feb 16th. https://ow.ly/TsaU50QxYmh Stay updated on all our events by following Fierce Life Sciences Events #FierceBiotech #FiercePharma #FierceHealthcare #Pharma #Biotech #WeAreFierce

Interesting insights and learnings from Theresa. Learn more about people and culture 👍

Exciting developments in the biopharma industry! In 2023, mergers and acquisitions took center stage, surpassing the dealmaking highs of recent years. The top 10 M&A deals in biopharma reached an impressive $115.8 billion, outpacing the totals of 2022, 2021, and 2020 at $65 billion, $53 billion, and $97 billion. It's clear that the industry is on a robust growth trajectory, paving the way for innovation and collaboration. Here's to a dynamic future in biopharma! Read the full report! https://ow.ly/APjZ50QxXNg Want to learn more about biopharma M&A, including how to build a comprehensive business development strategy? Join leading dealmaking experts from top biopharma companies at the Fierce BD&L Summit in San Francisco on March 11-12th. Save $300 when you register before Feb 16th. https://ow.ly/TsaU50QxYmh Stay updated on all our events by following Fierce Life Sciences Events #FierceBiotech #FiercePharma #FierceHealthcare #Pharma #Biotech #WeAreFierce

Exciting developments in the biopharma industry! In 2023, mergers and acquisitions took center stage, surpassing the dealmaking highs of recent years. The top 10 M&A deals in biopharma reached an impressive $115.8 billion, outpacing the totals of 2022, 2021, and 2020 at $65 billion, $53 billion, and $97 billion. It's clear that the industry is on a robust growth trajectory, paving the way for innovation and collaboration. Here's to a dynamic future in biopharma! Read the full report! https://ow.ly/APjZ50QxXNg Want to learn more about biopharma M&A, including how to build a comprehensive business development strategy? Join leading dealmaking experts from top biopharma companies at the Fierce BD&L Summit in San Francisco on March 11-12th. Save $300 when you register before Feb 16th. https://ow.ly/TsaU50QxYmh Stay updated on all our events by following Fierce Life Sciences Events #FierceBiotech #FiercePharma #FierceHealthcare #Pharma #Biotech #WeAreFierce

Great to see Lumentum's acquisition of Cloud Light Technology Limited get the recognition it deserves!!! And from our perspective, it was a really interesting deal to work on with lots of considerations we were weighing across multiple different jurisdictions. #mergersandacquisitions #techlaw #ai

When considering diversification, it’s important to remember the range of different bonds, sectors and individual companies we research. For example, the pharmaceutical industry has been experiencing a consolidation phase, with numerous mergers and acquisitions in recent years. Consequently, many companies have issued bonds to fund long-term growth, which can sometimes be at the expense of short-term cash flow. On the other hand, companies such as Apple have extremely strong cash flow even after heavy investment in research and development. Our research is consistent, but we also appreciate the sectors in which the underlying companies operate and their specific characteristics. #GimmeCredit #Diversification #InvestmentResearch

Did you know merger and acquisition deals are surging in biopharma, with the value of the top 10 M&A transactions in 2023 totaling over $115 billion? This sum far exceeds those of the past few years. 💰 In our latest from Kevin Barrett, we're outlining 7 key considerations that companies should keep in mind when undergoing one of these transactions: https://lnkd.in/g2f6BX7w